Byung Ok Kwak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Byung Ok Kwak has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Byung Wook Eun
Department of Pediatrics, Nowon Eulji University Hospital, Seoul, Korea
6 shared publications - Dong Hyun Kim
Department of Pediatrics, Inha University College of Medicine, Incheon, Korea
6 shared publications - Hyun Mi Kang
Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea
5 shared publications - Eun Hwa Choi
Department of Pediatrics, Chungnam National University Hospital, Daejeon, Korea
4 shared publications - Joon Kee Lee
Department of Pediatrics, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea
4 shared publications - Ki Wook Yun
Department of Pediatrics, Seoul National University Children’s Hospital, Seoul, Korea
4 shared publications
Latest Publications
- Open Access
- 25 August 2026
- Published by Springer Nature in Scientific Reports
Etiology of pediatric community-acquired pneumonia across Mycoplasma pneumoniae epidemic periods
- 25 August 2026
- Published by Springer Nature in Scientific Reports
Open AccessEtiology of pediatric community-acquired pneumonia across Mycoplasma pneumoniae epidemic periods
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41
Effectiveness of Nirsevimab in High-Risk Children Under 24 Months for Prevention of Respiratory Syncytial Virus Infection: A Systematic Review and Meta-Analysis
Kim YK, et al. J Korean Med Sci. 2026 Dec;41:e317. https://doi.org/10.3346/jkms.2026.41.e317
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41
Open AccessEffectiveness of Nirsevimab in High-Risk Children Under 24 Months for Prevention of Respiratory Syncytial Virus Infection: A Systematic Review and Meta-Analysis
Kim YK, et al. J Korean Med Sci. 2026 Dec;41:e317. https://doi.org/10.3346/jkms.2026.41.e317
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41
Emergence of Macrolide-Resistant Bordetella pertussis Harboring the A2047G Mutation During the 2024 Pertussis Outbreak in Korea
Kim Y, et al. J Korean Med Sci. 2026 Dec;41:e307. https://doi.org/10.3346/jkms.2026.41.e307
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41
Open AccessEmergence of Macrolide-Resistant Bordetella pertussis Harboring the A2047G Mutation During the 2024 Pertussis Outbreak in Korea
Kim Y, et al. J Korean Med Sci. 2026 Dec;41:e307. https://doi.org/10.3346/jkms.2026.41.e307
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (36)
Current Practice in the Diagnosis and Management of Mycoplasma pneumoniae Infections: A Survey of Korean Physicians in 2024
Choe YJ, et al. J Korean Med Sci. 2026 Sep;41:e229. https://doi.org/10.3346/jkms.2026.41.e229
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (36)
Open AccessCurrent Practice in the Diagnosis and Management of Mycoplasma pneumoniae Infections: A Survey of Korean Physicians in 2024
Choe YJ, et al. J Korean Med Sci. 2026 Sep;41:e229. https://doi.org/10.3346/jkms.2026.41.e229
- Open Access
- 31 December 2025
- Published by Korean Society of Kawasaki Disease in Kawasaki Disease
- Vol. 3 (2)
Treatment of Acute Stage of Kawasaki Disease Based on Updated 2024
Kawasaki disease (KD) is an acute febrile illness that primarily affects children under five years of age and can lead to coronary artery aneurysms if left untreated. High-dose intravenous immunoglobulin (IVIg) is the standard treatment. However, approximately 10%–20% of patients are refractory to this therapy and require additional treatments, including biologic agents such as infliximab, etanercept, or anakinra. As the use of these biologic agents has increased in recent years, concerns have been raised that biologics may suppress immune responses, potentially compromising the safety and immunogenicity of subsequent vaccinations, particularly live-attenuated vaccines. This study outlines the principles of vaccination in children with KD who have received biologic therapy. Key factors such as pharmacokinetics, mechanisms of action, and the duration of immunosuppressive effects should be considered when determining the optimal timing for vaccination. In patients with KD, biologics are typically administered once, often following IVIg, which may reduce the risk of vaccine-related adverse events while still allowing for adequate antibody responses. Further research is needed to establish evidence-based guidelines for safe and effective immunization in these patients.
- 31 December 2025
- Published by Korean Society of Kawasaki Disease in Kawasaki Disease
- Vol. 3 (2)
Open AccessTreatment of Acute Stage of Kawasaki Disease Based on Updated 2024
Kawasaki disease (KD) is an acute febrile illness that primarily affects children under five years of age and can lead to coronary artery aneurysms if left untreated. High-dose intravenous immunoglobulin (IVIg) is the standard treatment. However, approximately 10%–20% of patients are refractory to this therapy and require additional treatments, including biologic agents such as infliximab, etanercept, or anakinra. As the use of these biologic agents has increased in recent years, concerns have been raised that biologics may suppress immune responses, potentially compromising the safety and immunogenicity of subsequent vaccinations, particularly live-attenuated vaccines. This study outlines the principles of vaccination in children with KD who have received biologic therapy. Key factors such as pharmacokinetics, mechanisms of action, and the duration of immunosuppressive effects should be considered when determining the optimal timing for vaccination. In patients with KD, biologics are typically administered once, often following IVIg, which may reduce the risk of vaccine-related adverse events while still allowing for adequate antibody responses. Further research is needed to establish evidence-based guidelines for safe and effective immunization in these patients.
- Open Access
- 3 September 2025
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 46 (2) , 162-170
Diagnostic Accuracy of Serological Tests for Mycoplasma pneumoniae Infections in Children with Pneumonia, Based on Symptom Onset
Gahee Kim, M.D., Ki Wook Yun, M.D., Ph.D., Dayun Kang, M.D., Taek Jin Lee, M.D., Byung Wook Eun, M.D., Ph.D., Hyunju Lee, M.D., Ph.D., Yae-Jean Kim, M.D., Ph.D., Doo Ri Kim, M.D., Ph.D., Areum Shin, M.D., Hyun Mi Kang, M.D., Ph.D., Ye Ji Kim, M.D., Ph.D., Byung Ok Kwak, M.D., Ph.D., Younghee Lee, M.D., Ye Kyung Kim, M.D., Ph.D., Young June Choe, M.D., Ph.D., Woosuck Suh, M.D., Kyo Jin Jo, M.D., Kyung-Ran Kim, M.D., Eun Young Cho, M.D., Ph.D., Kyung Min Kim, M.D., Joon Kee Lee, M.D., Ph.D., and Su Eun Park, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2025.0125
- 3 September 2025
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 46 (2) , 162-170
Open AccessDiagnostic Accuracy of Serological Tests for Mycoplasma pneumoniae Infections in Children with Pneumonia, Based on Symptom Onset
Gahee Kim, M.D., Ki Wook Yun, M.D., Ph.D., Dayun Kang, M.D., Taek Jin Lee, M.D., Byung Wook Eun, M.D., Ph.D., Hyunju Lee, M.D., Ph.D., Yae-Jean Kim, M.D., Ph.D., Doo Ri Kim, M.D., Ph.D., Areum Shin, M.D., Hyun Mi Kang, M.D., Ph.D., Ye Ji Kim, M.D., Ph.D., Byung Ok Kwak, M.D., Ph.D., Younghee Lee, M.D., Ye Kyung Kim, M.D., Ph.D., Young June Choe, M.D., Ph.D., Woosuck Suh, M.D., Kyo Jin Jo, M.D., Kyung-Ran Kim, M.D., Eun Young Cho, M.D., Ph.D., Kyung Min Kim, M.D., Joon Kee Lee, M.D., Ph.D., and Su Eun Park, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2025.0125
- Open Access
- 15 May 2023
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 66 (5) , 182-189
COVID-19 in immunocompromised children and adolescents
Since coronavirus disease 2019 (COVID-19) became a global pandemic, concerns have arisen regarding the risks of COVID-19 in immunocompromised children and adolescents. Here we aimed to evaluate the clinical outcomes and risks of severe COVID-19 in immunocompromised pediatric patients. Previous studies reported that most children and adolescents receiving immunosuppressive medications have clinical presentations and favorable outcomes similar to those of the general pediatric population. Treatments and access to health services should not be interrupted in these populations, and continuous monitoring of the potential impact of variant strains on the risk of immunocompromised pediatric patients is warranted.
- 15 May 2023
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 66 (5) , 182-189
Open AccessCOVID-19 in immunocompromised children and adolescents
Since coronavirus disease 2019 (COVID-19) became a global pandemic, concerns have arisen regarding the risks of COVID-19 in immunocompromised children and adolescents. Here we aimed to evaluate the clinical outcomes and risks of severe COVID-19 in immunocompromised pediatric patients. Previous studies reported that most children and adolescents receiving immunosuppressive medications have clinical presentations and favorable outcomes similar to those of the general pediatric population. Treatments and access to health services should not be interrupted in these populations, and continuous monitoring of the potential impact of variant strains on the risk of immunocompromised pediatric patients is warranted.
- Open Access
- 1 January 2023
- Published by XMLink in Pediatric Infection & Vaccine
- Vol. 30 (2) , 104-110
A Case of Isolated Acute Pancreatitis Presenting With Epigastric Pain in an 8-Year-Old Child Infected With COVID-19
진주옥, et al. Pediatr Infect Vaccine. 2023 Aug;30(2):104-110. https://doi.org/10.14776/piv.2023.30.e11
- 1 January 2023
- Published by XMLink in Pediatric Infection & Vaccine
- Vol. 30 (2) , 104-110
Open AccessA Case of Isolated Acute Pancreatitis Presenting With Epigastric Pain in an 8-Year-Old Child Infected With COVID-19
진주옥, et al. Pediatr Infect Vaccine. 2023 Aug;30(2):104-110. https://doi.org/10.14776/piv.2023.30.e11
- Open Access
- 1 January 2023
- Published by XMLink in Pediatric Infection & Vaccine
- Vol. 30 (1) , 20-32
Etiology and Risk Factors of Community-Acquired Pneumonia in Hospitalized Children During the COVID-19 Pandemic in South Korea
강혜민, et al. Pediatr Infect Vaccine. 2023 Apr;30(1):20-32. https://doi.org/10.14776/piv.2023.30.e3
- 1 January 2023
- Published by XMLink in Pediatric Infection & Vaccine
- Vol. 30 (1) , 20-32
Open AccessEtiology and Risk Factors of Community-Acquired Pneumonia in Hospitalized Children During the COVID-19 Pandemic in South Korea
강혜민, et al. Pediatr Infect Vaccine. 2023 Apr;30(1):20-32. https://doi.org/10.14776/piv.2023.30.e3
- Open Access
- 15 March 2022
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 65 (3) , 108-114
Changes in age-specific seroprevalence of Japanese encephalitis virus and impact of Japanese encephalitis vaccine in Korea
The Japanese encephalitis (JE) virus is the leading cause of vaccine-preventable encephalitis in Asia. Since the introduction of a universal JE vaccination program and urbanization of Korea, the incidence of JE has dramatically decreased in Korea. However, recent JE cases have occurred, predominantly among unvaccinated adults and with a shift in age distribution. Here we aimed to review the changes in age-specific JE seroprevalence over time and discuss the implications of JE vaccination programs in Korea. Following the last epidemic in 1982–1983, mandatory vaccination for all children aged 3–15 years was conducted annually until 1994. However, JE has reemerged, predominantly affecting unvaccinated adults aged 40 years or older and demonstrating a shift in age distribution toward older populations. The age-specific seroprevalence of the JE virus in Korea has changed noticeably over time. Seropositivity in children and adolescents increased from 10%–59% in the 1970s to 90%–92% in the 1980s after the implementation of the JE vaccination program and increased further to 98% in 2012. No age-specific difference in the seroprevalence of JE was found, and appropriate levels of immunity to JE were maintained for all age groups. Continuous surveillance of the seroprevalence of JE is essential to establish a proper immunization policy in Korea.
- 15 March 2022
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 65 (3) , 108-114
Open AccessChanges in age-specific seroprevalence of Japanese encephalitis virus and impact of Japanese encephalitis vaccine in Korea
The Japanese encephalitis (JE) virus is the leading cause of vaccine-preventable encephalitis in Asia. Since the introduction of a universal JE vaccination program and urbanization of Korea, the incidence of JE has dramatically decreased in Korea. However, recent JE cases have occurred, predominantly among unvaccinated adults and with a shift in age distribution. Here we aimed to review the changes in age-specific JE seroprevalence over time and discuss the implications of JE vaccination programs in Korea. Following the last epidemic in 1982–1983, mandatory vaccination for all children aged 3–15 years was conducted annually until 1994. However, JE has reemerged, predominantly affecting unvaccinated adults aged 40 years or older and demonstrating a shift in age distribution toward older populations. The age-specific seroprevalence of the JE virus in Korea has changed noticeably over time. Seropositivity in children and adolescents increased from 10%–59% in the 1970s to 90%–92% in the 1980s after the implementation of the JE vaccination program and increased further to 98% in 2012. No age-specific difference in the seroprevalence of JE was found, and appropriate levels of immunity to JE were maintained for all age groups. Continuous surveillance of the seroprevalence of JE is essential to establish a proper immunization policy in Korea.